Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | OriCAR-017 |
| Synonyms | |
| Therapy Description |
OriCAR-017 is a chimeric antigen receptor (CAR)-T cell therapy that targets two epitopes of GPRC5D, which may induce antitumor activity (PMID: 36725117). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| OriCAR-017 | OriCAR 017|OriCAR017 | GPRC5D Immune Cell Therapy 4 | OriCAR-017 is a chimeric antigen receptor (CAR)-T cell therapy that targets two epitopes of GPRC5D, which may induce antitumor activity (PMID: 36725117). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06271252 | Phase I | OriCAR-017 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | Recruiting | USA | 0 |